From the Journals

Targeting obesity could slow brain aging in psychosis


 

FROM THE JOURNAL OF PSYCHIATRIC RESEARCH

Being overweight or obese could be a risk factor for the kind of brain aging seen in some patients with first-episode psychosis (FEP), new research suggests.

The investigators found significant associations between BrainAGE scores and a diagnosis of FEP (P = .005), overweight/obesity category (P = .007), and body mass index (P = .02). Furthermore, the association found between BrainAGE score and BMI was related to an association between BrainAGE score and weight (P = .009), but not to height (P = .13).

“These findings raise the possibility that targeting metabolic health in FEP and intervening already at the level of overweight/obesity could slow brain aging in schizophrenia and related disorders,” reported Marian Kolenic of the National Institute of Mental Health in Klecany, Czech Republic, and his coauthors.

The researchers recruited 120 patients with FEP as defined by the ICD-10 during their first psychiatric hospitalization. People with psychotic mood disorders were excluded.

“We wanted to recruit participants at the early stages of illness, to minimize the effects of illness and medications on brain structure,” the investigators wrote.

One hundred fourteen healthy controls were recruited through advertisements, and exclusion criteria included a lifetime history of any psychiatric disorders and the presence of psychotic disorders in either first- or second-degree relatives.

All participants were asked about their medical history, including their use and/or abuse of substances. Fasting blood samples were collected on the scanning day.

Pages

Recommended Reading

Class of 2015: New drugs projected to earn billions and billions
MDedge Endocrinology
Testosterone tied to face recognition in men with schizophrenia
MDedge Endocrinology
Antipsychotic prescriptions drop for children, but rise among teens, young adults
MDedge Endocrinology
Researchers highlight gaps in diabetes screening in patients on antipsychotics
MDedge Endocrinology
Antipsychotics may double to triple diabetes risk in youth
MDedge Endocrinology
VIDEO: Lifestyle intervention blocks antipsychotic-associated weight gain
MDedge Endocrinology
Prepsychosis links with elevated metabolic syndrome
MDedge Endocrinology
Statement warns of drugs causing or exacerbating heart failure
MDedge Endocrinology
Type 2 diabetes peer-led intervention in primary care tied to improved depression symptoms
MDedge Endocrinology
Liraglutide produced cardiometabolic benefits in patients with schizophrenia
MDedge Endocrinology